In 2018, Chris White was diagnosed with anorectal mucosal melanoma, a rare and aggressive type of malignant metastatic cancer. After 18 months of standard treatment, he was out of options. Chris’ doctors referred him to a clinical trial for tumor infiltrating lymphocytes (TIL). After joining the trial and beginning the process, his baseline scans revealed a brain metastasis and excluded him from continuing the trial until he could treat and prove the brain mass was stable or in reduction. The catch is there was only 10 business days to do so, no exceptions. Upon receiving this information, his doctors told him this was an “impossible timeline to make, but we will try. If he could not reenter the trial, then settling his affairs and hospice is the only thing left.” Well, Chris did do the impossible and made the timeline and was able to resume the trial at the very last moment. In January of 2020 he spent 12 days in the hospital and received his TIL infusion. Chris is the last clinical trial patient to be dosed in the 1st ever FDA approved, advanced autologous cell therapy for any solid tumor. Within nine months, his scans were showing a complete metabolic response and his cancer has been eradicated ever since.

In his own words, Chris shares the story of his treatment journey and his road to advanced therapy.

свернуть